RESUMEN
BACKGROUND/OBJECTIVES: Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of phenylalanine hydroxylase. A low phenylalanine (Phe) diet is used to treat PKU. The diet is very restrictive, and dietary adherence tends to decrease as patients get older. Methods to improve dietary adherence and blood Phe control are continuously under investigation. SUBJECTS/METHODS: A new formula Phe-neutral amino acid (PheLNAA) has been tested in this study with the purpose of improving the compliance and lowering blood phenylalanine. The formula has been tested for nitrogen balance, and it is nutritionally complete. It is fortified with more nutritional additives that can be deficient in the PKU diet, such as B12, Biotin, DHA, Lutein and increased levels of large neutral amino acids to help lower blood Phe. The new formula has been tested on 12 patients with a loading test of 4 weeks. RESULTS: Fifty-eight percent of patients had a significant decline in blood Phe concentration from baseline throughout the study. The PheLNAA was well tolerated with excellent compliance and without illnesses during the study. CONCLUSIONS: In conclusion, the new formula is suitable for life-long treatment of PKU, and it offers the PKU clinic a new choice for treatment.
Asunto(s)
Aminoácidos Neutros/administración & dosificación , Alimentos Formulados , Alimentos Fortificados , Fenilalanina/sangre , Fenilcetonurias/dietoterapia , Adolescente , Femenino , Humanos , Masculino , Cooperación del Paciente/psicología , Fenilcetonurias/sangre , Fenilcetonurias/psicología , Resultado del TratamientoRESUMEN
A 16-year-old adolescent with mild hyperphenylalaninaemia was given a high-protein 'body building' supplement twice daily, causing headaches, decreased school performance and mild depression. All symptoms disappeared after cessation of the supplement. The phenylalanine hydroxylase mutation H170D/IVS1nt5G>T was found to be responsive to tetrahydrobiopterin with significant decrease in blood phenylalanine concentration and increase in tyrosine blood content. A brain phenylalanine level of 0.5 mmol/L was initially documented, which decreased to the normal carrier range of 0.2 mmol/L within one month of discontinuance of the protein supplement. At present, the patient is on a normal diet without phenylalanine restriction.
Asunto(s)
Aminoácidos/administración & dosificación , Aminoácidos/efectos adversos , Biopterinas/análogos & derivados , Depresión/etiología , Suplementos Dietéticos , Cefalea/etiología , Fenilcetonurias/complicaciones , Adolescente , Biopterinas/administración & dosificación , Depresión/inducido químicamente , Relación Dosis-Respuesta a Droga , Cefalea/inducido químicamente , Humanos , Masculino , Mutación , Fenilalanina/sangre , Fenilalanina Hidroxilasa/genética , Fenilcetonurias/genética , SomatotiposRESUMEN
Malonyl CoA decarboxylase (MCD) is an enzyme involved in the metabolism of fatty acids synthesis. Based on reports of MCD deficiency, this enzyme is particular important in muscle and brain metabolism. Mutations in the MCD gene result in a deficiency of MCD activity, that lead to psychomotor retardation, cardiomyopathy and neonatal death. To date however, only a few patients have been reported with defects in MCD. We report here studies of a patient with MCD deficiency, who presented with hypotonia, cardiomyopathy and psychomotor retardation. DNA sequencing of MCD revealed a homozygous intronic mutation, specifically a -5 C to T transition near the acceptor site for exon 3. RT-PCR amplification of exons 2 and 3 revealed that although mRNA from a normal control sample yielded one major DNA band, the mutant mRNA sample resulted in two distinct DNA fragments. Sequencing of the patient's two RT-PCR products revealed that the larger molecular weight fragments contained exons 2 and 3 as well as the intervening intronic sequence. The smaller size band from the patient contained the properly spliced exons, similar to the normal control. Western blotting analysis of the expressed protein showed only a faint band in the patient sample in contrast to a robust band in the control. In addition, the enzyme activity of the mutant protein was lower than that of the control protein. The data indicate that homozygous mutation in intron 2 disrupt normal splicing of the gene, leading to lower expression of the MCD protein and MCD deficiency.
Asunto(s)
Encefalopatías Metabólicas Innatas/enzimología , Encefalopatías Metabólicas Innatas/genética , Encéfalo/enzimología , Carboxiliasas/deficiencia , Carboxiliasas/genética , Genes/genética , Intrones/genética , Mutación/fisiología , Sitios de Empalme de ARN/genética , Secuencia de Bases , Encéfalo/anomalías , Encéfalo/fisiopatología , Análisis Mutacional de ADN , ADN Complementario/análisis , ADN Complementario/genética , Ácidos Grasos/genética , Ácidos Grasos/metabolismo , Homocigoto , Humanos , Malonil Coenzima A/genética , Malonil Coenzima A/metabolismo , ARN Mensajero/análisis , ARN Mensajero/genéticaRESUMEN
Children with inborn errors of urea synthesis accumulate ammonium and other nitrogenous precursors of urea, leading to episodic coma and a high mortality rate. We used alternative pathways for the excretion of waste nitrogen as substitutes for the defective ureagenic pathways in 26 infants. These pathways involve synthesis and excretion of hippurate after sodium benzoate administration, and of citrulline and argininosuccinate after arginine supplementation. The children were treated for seven to 62 months; 22 survived. The mean plasma level of ammonium ( +/- S.E.) was 36 +/- 2 mumol per liter, and that of benzoate was 1.5 +/- 1.0 mg per deciliter. Alternative pathways accounted for between 28 and 59 per cent of the total "effective" excretion of waste nitrogen. Nineteen infants had normal height, weight, and head circumference, and 13 had normal intellectual development. Activation of alternative pathways of waste nitrogen excretion can prolong survival and improve clinical outcome in children with inborn errors of urea synthesis.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/terapia , Amoníaco/sangre , Arginina/administración & dosificación , Benzoatos/administración & dosificación , Nitrógeno/metabolismo , Urea/biosíntesis , Errores Innatos del Metabolismo de los Aminoácidos/dietoterapia , Errores Innatos del Metabolismo de los Aminoácidos/tratamiento farmacológico , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Aminoácidos Esenciales/administración & dosificación , Argininosuccinato Sintasa/deficiencia , Aciduria Argininosuccínica , Ácido Benzoico , Carbamoil-Fosfato Sintasa (Amoniaco)/deficiencia , Preescolar , Citrulina/sangre , Coma/etiología , Femenino , Humanos , Lactante , Recién Nacido , Infusiones Parenterales , Masculino , Enfermedad por Deficiencia de Ornitina CarbamoiltransferasaRESUMEN
Cultures of skin fiibroblasts from a patient with Fabry's disease showed an accumulation of the glycolipid, galactosyl-galactosyl-glucosyl ceramide. Such cells also showed metachromasia on staining with toluidine blue and a markedly elevated acid mucopolysaccharide content.